Clinical trials: WHIM, open to volunteers
Metastatic Breast Cancer
Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) is a particularly aggressive type of breast cancer that is difficult to treat. Unlike other forms of breast cancer, TNBC tends to relapse earlier and spread more quickly to other parts of the…
- Trial name
- EXIGENCE (NCT06962163)
- Testing
- [68Ga]Ga-PentixaFor PET/CT
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Institut Cancerologie de l'Ouest
Small Cell Lung Carcinoma (SCLC)
Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)
[68Ga]Ga-PentixaFor PET-CT will be performed in patients with Small cell lung cancer (SCLC) to confirm the targeting of CXCR4 by [68Ga]Ga-PentixaFor
- Trial name
- PASSIFLORE (NCT07007325)
- Testing
- [68Ga]Ga-PentixaFor
- Where
- 3 sites in France
- Volunteers
- 15 people
- Sponsor
- Institut Cancerologie de l'Ouest
Shwachman-Diamond Syndrome, SDS
Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe…
- Conditions
- Shwachman-Diamond Syndrome, SDS, IBMF, Congenital Neutropenia
- Trial name
- SDS-GPS (NCT06999954)
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Shwachman-Diamond Syndrome Alliance Inc
Multiple Myeloma
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Multiple myeloma is a disease mainly located in participants bones. Usually a participants physician arrives at this diagnosis by doing blood tests and ordering standard of care imaging tests (18F-FDG PET/CT and maybe additional…
- Trial name
- NCT06871176
- Testing
- [68Ga]Ga-PentixaFor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Neutropenia
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are…
- Trial name
- NCT06056297
- Testing
- Mavorixafor
- Where
- 114 sites in United States, Argentina and 23 more
- Volunteers
- 176 people
- Sponsor
- X4 Pharmaceuticals
Lymphoma, Multiple Myeloma
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia
- Trial name
- NCT04504526
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Indolent B-Cell Non-Hodgkin Lymphoma
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma.
- Trial name
- PentixaFor (NCT06461182)
- Testing
- Ga-68-CXCR4
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- Koo Foundation Sun Yat-Sen Cancer Center
Metastatic Pancreatic Ductal Adenocarcinoma
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafortide and cosibelimab in patients with metastatic PDAC who progressed…
- Trial name
- NCT06981806
- Testing
- Balixafortide, Cosibelimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arsen Osipov
Advanced Solid Tumor, Multiple Myeloma
Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.
Phase 1, monocentric, open labeled, no profit "Microdose" trial. A single microdose of the new [68Ga]Ga-R54 PET radiopharmaceutical directed against CXCR4 will be injected into patients with advanced solid tumor or multiple…
- Trial name
- NCT07577206
- Testing
- [68Ga]Ga-R54 PET/CT
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute, Naples
CXCR4, PET/CT
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
Hematological malignancies continue to pose significant clinical challenges due to their high incidence, heterogeneous biology, and substantial mortality.
- Conditions
- CXCR4, PET/CT, Hematological Malignancy
- Trial name
- NCT05255926
- Testing
- 68Ga-pentixafor, PET/CT
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhongnan Hospital
Myocardial Infarction, Myocardial Injury
Lymphatic Organs and Myocardium After Myocardial Infarction
The adaptive immune response plays an important role in myocardial healing and remodeling after acute myocardial infarction in patients. Therefore, the involved lymphocytes represent a novel target for therapeutic interventions.
- Conditions
- Myocardial Infarction, Myocardial Injury, Myocardial Inflammation
- Trial name
- LOMI (NCT05519735)
- Testing
- Multimodality Imaging
- Where
- 2 sites in Germany
- Volunteers
- 57 people
- Sponsor
- Wuerzburg University Hospital
Influenza, Acute Respiratory Distress Syndrome
The Role of Cxcr4Hi neutrOPhils in InflueNza
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research.
- Trial name
- CHOPIN (NCT06254313)
- Testing
- Additional tubes and LBA
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Bordeaux
Cushing s Syndrome
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms.
- Trial name
- NCT07350707
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking Union Medical College Hospital
CXCR4-related Disease, Tumor
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
- Conditions
- CXCR4-related Disease, Tumor, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690736
- Testing
- CXCR4 PET/CT Imaging
- Where
- 3 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
WHIM, Warts
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
Background: Warts, hypogammaglobulinemia, infections and myelokathexis syndrome (WHIMs) is a rare disorder that affects the immune system. People with WHIMs can have severe infections all over their body.
- Conditions
- WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency
- Trial name
- NCT07775313
- Testing
- Busulfan, Palifermin, Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non-Hodgkin Lymphoma, Multiple Myeloma
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and…
- Conditions
- Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease
- Trial name
- NCT05093335
- Testing
- [68Ga]-Pentixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center